Joel Greenblatt Immuno Gen, Inc. Transaction History

Gotham Asset Management, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.46 - $29.95 $21,767 - $52,322	1,747 Added 14.23%	14,025 $415,000
Q3 2023 Nov 14, 2023	SELL	$14.09 - $19.87 $73,732 - $103,979	-5,233 Reduced 29.88%	12,278 $194,000
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $65,666 - $351,095	17,511 New	17,511 $330,000
Q4 2022 Feb 14, 2023	SELL	$4.55 - $6.31 $9 - $12	-2 Reduced 0.01%	15,674 $77,000
Q3 2022 Nov 14, 2022	SELL	$4.48 - $6.47 $15,008 - $21,674	-3,350 Reduced 17.61%	15,676 $75,000
Q2 2022 Aug 15, 2022	BUY	$3.15 - $5.76 $11,503 - $21,035	3,652 Added 23.75%	19,026 $86,000
Q3 2021 Nov 15, 2021	SELL	$5.02 - $6.59 $6,716 - $8,817	-1,338 Reduced 8.01%	15,374 $87,000
Q2 2021 Aug 16, 2021	SELL	$5.79 - $8.6 $285,609 - $424,220	-49,328 Reduced 74.69%	16,712 $110,000
Q1 2021 May 17, 2021	BUY	$6.5 - $10.53 $294,963 - $477,840	45,379 Added 219.64%	66,040 $535,000
Q4 2020 Feb 16, 2021	SELL	$3.7 - $7.66 $9,120 - $18,881	-2,465 Reduced 10.66%	20,661 $133,000
Q3 2020 Nov 16, 2020	SELL	$3.45 - $4.89 $964,975 - $1.37 Million	-279,703 Reduced 92.36%	23,126 $83,000
Q2 2020 Aug 13, 2020	BUY	$3.32 - $5.34 $662,615 - $1.07 Million	199,583 Added 193.31%	302,829 $1.39 Million
Q1 2020 May 15, 2020	BUY	$2.12 - $6.8 $46,389 - $148,797	21,882 Added 26.89%	103,246 $352,000
Q4 2019 Feb 14, 2020	BUY	$2.25 - $5.8 $183,069 - $471,911	81,364 New	81,364 $415,000
Q4 2017 Feb 14, 2018	SELL	$5.07 - $7.92 $1.24 Million - $1.93 Million	-243,949 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$5.4 - $8.47 $1.32 Million - $2.07 Million	243,949	243,949 $1.87 Million

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.